Pharmaron Beijing Co., Ltd. (SHE:300759)
China
· Delayed Price · Currency is CNY 29.28
-1.64 (-5.30%)
Apr 29, 2026, 10:45 AM CST
Pharmaron Beijing Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 14,073 | 12,269 | 11,533 | 10,240 | 7,419 | Upgrade
|
| Other Revenue | 21.9 | 6.4 | 4.61 | 26.19 | 24.48 | Upgrade
|
| Revenue | 14,095 | 12,276 | 11,538 | 10,266 | 7,444 | Upgrade
|
| Revenue Growth (YoY) | 14.82% | 6.39% | 12.39% | 37.92% | 45.00% | Upgrade
|
| Cost of Revenue | 9,205 | 8,091 | 7,422 | 6,502 | 4,768 | Upgrade
|
| Gross Profit | 4,890 | 4,184 | 4,116 | 3,764 | 2,676 | Upgrade
|
| Selling, General & Admin | 2,043 | 1,843 | 1,859 | 1,728 | 1,022 | Upgrade
|
| Research & Development | 576.02 | 469.26 | 448.28 | 282.32 | 151.77 | Upgrade
|
| Other Operating Expenses | 145.95 | 109.7 | 82.75 | 66.52 | 44.04 | Upgrade
|
| Operating Expenses | 2,845 | 2,465 | 2,426 | 2,098 | 1,229 | Upgrade
|
| Operating Income | 2,045 | 1,719 | 1,690 | 1,667 | 1,448 | Upgrade
|
| Interest Expense | -192.81 | -243.72 | -182.19 | -167.31 | -83.07 | Upgrade
|
| Interest & Investment Income | 39.39 | 615.7 | 78.95 | 109.74 | 371.99 | Upgrade
|
| Currency Exchange Gain (Loss) | 2.65 | 31.43 | 147 | -42.39 | -3.16 | Upgrade
|
| Other Non Operating Income (Expenses) | -5.32 | -4.22 | -3.61 | -2.54 | -1.39 | Upgrade
|
| EBT Excluding Unusual Items | 1,889 | 2,118 | 1,730 | 1,564 | 1,732 | Upgrade
|
| Impairment of Goodwill | - | -73.54 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -35.97 | 1.54 | 18.75 | 68.09 | 119.59 | Upgrade
|
| Gain (Loss) on Sale of Assets | -20 | -33.67 | -9.15 | -15.3 | -4.25 | Upgrade
|
| Other Unusual Items | 79.37 | 78.51 | 98.48 | 49.5 | 63.73 | Upgrade
|
| Pretax Income | 1,913 | 2,091 | 1,838 | 1,666 | 1,911 | Upgrade
|
| Income Tax Expense | 357.52 | 377.1 | 256.11 | 314.25 | 290.92 | Upgrade
|
| Earnings From Continuing Operations | 1,555 | 1,714 | 1,582 | 1,352 | 1,620 | Upgrade
|
| Minority Interest in Earnings | 108.71 | 79.19 | 19.32 | 22.47 | 40.95 | Upgrade
|
| Net Income | 1,664 | 1,793 | 1,601 | 1,375 | 1,661 | Upgrade
|
| Net Income to Common | 1,664 | 1,793 | 1,601 | 1,375 | 1,661 | Upgrade
|
| Net Income Growth | -7.22% | 12.01% | 16.48% | -17.24% | 41.68% | Upgrade
|
| Shares Outstanding (Basic) | 1,762 | 1,770 | 1,772 | 1,774 | 1,781 | Upgrade
|
| Shares Outstanding (Diluted) | 1,771 | 1,773 | 1,775 | 1,776 | 1,820 | Upgrade
|
| Shares Change (YoY) | -0.11% | -0.11% | -0.05% | -2.40% | 1.97% | Upgrade
|
| EPS (Basic) | 0.94 | 1.01 | 0.90 | 0.78 | 0.93 | Upgrade
|
| EPS (Diluted) | 0.94 | 1.01 | 0.90 | 0.77 | 0.91 | Upgrade
|
| EPS Growth | -7.12% | 12.13% | 16.54% | -15.21% | 38.94% | Upgrade
|
| Free Cash Flow | 551.97 | 536.02 | -111.78 | -807.04 | -34.78 | Upgrade
|
| Free Cash Flow Per Share | 0.31 | 0.30 | -0.06 | -0.45 | -0.02 | Upgrade
|
| Dividend Per Share | 0.200 | 0.200 | 0.200 | 0.200 | 0.200 | Upgrade
|
| Dividend Growth | - | - | - | - | 50.04% | Upgrade
|
| Gross Margin | 34.70% | 34.09% | 35.67% | 36.67% | 35.95% | Upgrade
|
| Operating Margin | 14.51% | 14.01% | 14.64% | 16.23% | 19.45% | Upgrade
|
| Profit Margin | 11.80% | 14.61% | 13.88% | 13.39% | 22.31% | Upgrade
|
| Free Cash Flow Margin | 3.92% | 4.37% | -0.97% | -7.86% | -0.47% | Upgrade
|
| EBITDA | 3,052 | 2,597 | 2,431 | 2,227 | 1,852 | Upgrade
|
| EBITDA Margin | 21.65% | 21.16% | 21.07% | 21.70% | 24.88% | Upgrade
|
| D&A For EBITDA | 1,007 | 878.18 | 741.2 | 560.76 | 404.64 | Upgrade
|
| EBIT | 2,045 | 1,719 | 1,690 | 1,667 | 1,448 | Upgrade
|
| EBIT Margin | 14.51% | 14.01% | 14.64% | 16.23% | 19.45% | Upgrade
|
| Effective Tax Rate | 18.69% | 18.03% | 13.94% | 18.86% | 15.22% | Upgrade
|
| Revenue as Reported | 14,095 | 12,276 | 11,538 | 10,266 | 7,444 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.